|
INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients
|
09 Nov, 2020 |
|
INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update
|
05 Nov, 2020 |
|
INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5
|
29 Oct, 2020 |
|
INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery
|
05 Oct, 2020 |
|
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29
|
23 Sep, 2020 |
|
INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression
|
16 Sep, 2020 |
|
INmune Bio, Inc. to Participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020.
|
14 Sep, 2020 |
|
INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune™ Therapy
|
03 Sep, 2020 |
|
INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID19 Patients
|
01 Sep, 2020 |
|
European Patent Granted Covering INmune Bio’s XPro1595
|
13 Aug, 2020 |
|
INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update
|
05 Aug, 2020 |
|
INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020
|
03 Aug, 2020 |
|
INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results
|
31 Jul, 2020 |
|
INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm
|
27 Jul, 2020 |
|
Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
|
20 Jul, 2020 |
|
INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
|
20 Jul, 2020 |
|
INmune Bio, Inc. Prices Public Offering of Common Stock
|
15 Jul, 2020 |
|
INmune Bio, Inc. Announces Proposed Public Offering of Common Stock
|
15 Jul, 2020 |
|
INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease
|
13 Jul, 2020 |
|
INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020
|
09 Jul, 2020 |
|
INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS
|
11 Jun, 2020 |
|
Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc.
|
19 May, 2020 |
|
INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update
|
14 May, 2020 |
|
INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer
|
11 May, 2020 |
|
INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call
|
06 May, 2020 |
|
INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020
|
28 Apr, 2020 |
|
Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer
|
23 Apr, 2020 |
|
INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells
|
22 Apr, 2020 |
|
INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19
|
20 Apr, 2020 |
|
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH
|
11 Mar, 2020 |
|
INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17
|
05 Mar, 2020 |
|
INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results
|
27 Feb, 2020 |
|
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
|
10 Feb, 2020 |
|
INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals
|
02 Jan, 2020 |
